Pharmaceutical - Financial, Anti-Arthritics/Rheumatics


Popular Filters

New treatment funded for severe gout in New Zealand


Patients with severe gout will soon have a new treatment option as New Zealand’s Pharmaceutical Management…

AdenuricAnti-Arthritics/RheumaticsfebuxostatFinancialMenariniNew ZealandPharmaceuticalRegulation

NIH in $235 million partnership for lupus and other complex disease treatments

NIH in $235 million partnership for lupus and other complex disease treatments


In the USA, the Lupus Foundation of America says that it will partner with the Foundation for the National…


DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development


The development program for MK-8931, a novel investigational oral beta-amyloid precursor protein site-cleaving…

Anti-Arthritics/RheumaticsFinancialFosamaxMerck & CoMK-8931NeurologicalNorth AmericaPharmaceuticalResearch

Karo Bio gets first milestone in Pfizer collaboration


Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Galapagos and Servier celebrate late stage discovery milestone


Belgium-based Galapagos (Euronext: GLPG) has announced a late stage discovery milestone for small molecules…


GlaxoSmithKline buys rights to MorphoSys RA drug candidate for up to $577 million


German biotech firm MorphoSys (FSE: MOR) yesterday (June 3) saw its shares leap as much as 6%, as it…


Specialty drug costs account for over 50% of the total cost of care for RA and hepatitis C patients in USA


According to two new studies by Prime Therapeutics, a leading US pharmacy benefit manager, rheumatoid…

Anti-Arthritics/RheumaticsAnti-viralsBiotechnologyFinancialHealthcareNorth AmericaPharmaceutical

US Judge imposes nearly $322 million fine on Merck & Co for illegal marketing


US drug giant Merck & Co (NYSE: MRK) was sentenced by US District Court Judge Patti Saris in Boston to…

Anti-Arthritics/RheumaticsFinancialLegalMerck & CoNorth AmericaPharmaceuticalVioxx

Milestone for ChemoCentryx as GSK exercises license option


UK pharma giant GlaxoSmithKline (LSE: GSK) has exercised its option to obtain an exclusive license for…


Skyepharma updates on Exparel, Flutiform and financial position


UK drug developer SkyePharma (LSE: SKP) yesterday issued an update on its R&D pipeline and provided an…

Anti-Arthritics/RheumaticsExparelFinancialFlutiformLodotraPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Merck & Co highlights pipeline progress; plans eight US filings in 2012-


US pharma giant Merck & Co (NYSE:MRK) hosted an upbeat R&D and Business Briefing yesterday, where it…

Anti-Arthritics/RheumaticsBridonCardio-vascularFinancialMerck & CoNeurologicalodanacatibOncologyPharmaceuticalRegulationResearchsuvorexantTredaptive

Back to top